Las Vegas, Nevada
October 3-6, 2026
Wynn Las Vegas
Booth #326
Connect with Caris Life Sciences at CAP 2026
Join Caris Life Sciences® at the upcoming CAP 2026 in Las Vegas, Nevada. Visit our team at booth #326 to discover the latest innovations in precision medicine and learn how our products and services are leading the molecular revolution.
Precision Medicine Begins with Pathology
Caris is built on pathology excellence and a foundation of comprehensive diagnostic standards and innovation. Our pathology program drives precision oncology by combining expert interpretation with advanced molecular profiling technologies.
Behind every innovation at Caris is a team of pathologists who never forget the human side of science. Our 31 board-certified anatomic and clinical pathologists combine deep subspecialty expertise with advanced AI and digital pathology to bring clarity to complexity and confidence to patient care.
Pathologists are the clinical and molecular translators of patient care. We provide physician-to-physician consultation for our ordering providers. From resolving diagnostic uncertainty to integrating tissue and blood profiling, our team ensures that precision medicine is more than a process, it is a partnership.
Schedule a Meeting
Products At-a-Glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure® delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Cancer Seek
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.